retatrutide 12 mg Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD Retatrutide: The New Triple-Agonist Weight

That combination is likely why retatrutide's trial results have outperformed every approved weight loss drug on the market

The extended half-life means 2448 hour delays cause minimal appetite rebound, but avoid doubling doses to compensatethat amplifies GI side effects without improving weight loss outcomes

Retatrutide is once-weekly and can be done any day at any time, but most users pick a fixed weekly day for consistency

Wharton S, Davies M, Dicker D, et al

Key differentiator Laboratory assays show that retatrutide activates the GIP and GLP-1 receptors at lower concentrations than the glucagon receptor

But investors and analysts think only a handful of companies have what it takes to make it big in the market and next year could determine which one comes out on top